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The aim of this study was to evalu ate the acute effects of 
5- methoxypsoralen (5-MOP) on the melatonin secretion 
in humans. Eleven norm al volunteers were investigated 
before (drug-free) and after 6-day periods of trea tment with 
oralS-MOP, first ad ministered daily at 9 A.M. and after a 
l-week free interval ad ministered daily at 9 P.M. Under 
nyctemeral conditions, the plasma melatonin levels were 
evaluated over a 24-h period in each session by hou rly 
blood sa mples and radioimmunoassay. T he sensitivity of 
the retina to light was also evaluated by means of electro-
retinography performed at 11 A. M. before and after a morn-
in g administration of 5-MOP. 
5 -Methoxypsoralen (5-M OP) is one of the linea r furocou-marins, compounds well known for their skin-photosen-sitizing activity [1] . The scientifi c interest in pso ralens has grown cons iderably in the las t decade Sll1ce the climcal introduction of psoralen photochemotherapy (P UV A) for 
the treatment of psorias is and other skin diseases [2]. 
O n th e other han d, N-acetyl-5-methoxytryptamine (mela-
tonin) represents the best avail able index of the pineal gland fun c-
tion . T he melatonin secretion undergoes a clear circadian rhyth-
micity with high plasma levels during the dark-phase of the day . 
In addition, its secreti on is inhibited by intense light in ani;nals 
and humans (over 2500 lu x) [3,4]. Although the ro le of melatonin 
remains unclear, it seems to be in volved in the control of certa in 
biologic rh ythms and their related physiologic functions [5]. This 
secretion has also been repo rted to be altered in various pathologic 
circumstances such as psychiatric disorders [6]. 
Among the pharmacologic facto rs acti ng on melatonin secre-
tion, psora len may be of particular interest since 8-methoxy-
psoralen (8-MOP) has recently been reported to increase the plasma 
level of melatonin in humans [3] and in rats [7]. 
We report here preliminary studies of the effects on melatonin 
secretion of 5-MOP ad ministrat ion in humans at different times 
of the day. 
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Plasma levels of melatonin were significantly increased 
from the second hour after 5-MOP administration. The 
hourl y mean levels were significantly higher after 5-MOP 
administration compared to baseline values. This increased 
secretion was more pronounced after evening than after 
morning administration. Also, 5-MOP increases the sen-
sitivity of the retina to light under photopic conditions and 
in the early stages of the dark adaptation period , as observed 
under scotopic conditions . J Invest D ermatol 89: 152-155, 
1987 
MATERIALS AND METHODS 
Eleven normal men (mean age, 24 .3 ± 2.1 yea rs) were inves ti-
gated before and after psoralen administration . The volunteers 
(medica l students) were physically healthy, as assessed by clinical 
and biologic inves tiga tions , and were dru g- free for at least 1 
month. After their consent was obta ined, th ey were ad mitted to 
the psychiatric department of the Nice Uni versity. Plasma levels 
of melatonin were evaluated over a 24-h period under 3 different 
conditions. First, in standard nyctemeral conditi ons (baseline) ; 
second , on the 6th day of a psoralen treatment, 40 m g of 5-MOP 
(Psoraderm , Goupil Inc.) was orally administered at 9 A.M. each 
da y; and third , after a 1-week dru g-free period , on the 6th day 
of a similar trea tment, 5-MOP was administered daiJy at 9 P.M. 
During each session, the subj ects were placed under nyctemeral 
conditions, in bed for a 24-h peri od, illuminati on being of more 
than 2000 lux from 6:30-21 :30 hours and redu ced to 50 lu x there-
after. 
The effects of5-MOP on eye sensitivity was assessed by means 
of electroretinograph y performed in each subj ect at 11 A.M in 
baseline conditions and after morning administration of 5-MOP 
at 9 A. M. E lectroretinogram (ERG) consisted of recording the 
retina response to light under different conditions (Panthops ERG). 
Responses were first elicited in photopic conditions, in darkness 
without a peri od of dark adaptation, and by a series of 10-/-Ls 
fl ashes of short-wavelength light stimuli (white and orange), and 
were monitored at the topically anesthetized corn ea by a bipolar 
contact lens electrode (inserted in dim red illumination). Reco rd-
ings were then performed und er scotopic conditions. The pa-
tients, after a sustained dark adaptation (20 min) , were first sub-
mitted to a single fla sh of bright (2500 lux) w hite li ght and th en 
to single 10-/-Ls fl ashes of short-wavelength light every 2 min for 
at least 16 min . These conditions of recordin g were strictly similar 
before and after trea tment w ith 5-MOP. Amplitudes, from base-
line to peak of b-wave values in photopic conditions and of b2-
wave values in scotopic conditions were th en considered . 
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Table I. Pl as ma Levels of Immunoreactive M elatonin (nmol/ liter) 
8 A.M . 9 A.M . '1 0 A.M. 11 A.M . 12 P.M. 1 P.M. 
Baseline 0.22 ± 0.06 0.21 ± 0.05 0. 18 ± 0.05 0. 16 ± 0.05 0. 15 ± 0.03 0. 14 ± 0.05 
1 
With 5-MOP 0.24 ± 0.06 1 0.22 ± 0.06 0.23 ± 0.04 0.24 ± 0.05 0.28 ± 0.05" 0.30 ± 0.09" 
I-tes t NS NS NS p < 0.0'1 P < 0.00 '1 P < 0.01 
8 P.M. 9 P.M. 10 P.M. 11 P.M. 12 A. M. 1 A.M. 
Baseline 0.20 ± 0.04 0.21 ± 0.04 0. 'I 9±0.04 0.31 ± 0.04/' 0.42 ± 0.05" 0.47 ± 0.06" 
1 
With 5-MOP 0.20 ± 0.05 1 0.22 ± 0.03 0.30 ± 0.06 0.55 ± 0. 11 b 0.64 ± 0. 11 /' 0.89 ± 0.14b 
I-test NS NS P < 0.0 1 P < 0.001 P < 0.001 P < 0.001 
E leven norm al subjects arc indi ca ted fro m 8 A . M . un til 1 P. M . and fro m 8 P. M . until 1 A.M . • before (baseline) and after a 6-day period o frrc:1t lTl c nt wi th 5-MOP ad ministered 
fi rs t at 9 A.M. Jnd the ll at 9 P. M . cach da y. 
' p < 0.0 1 vs 9 A.M. 
'p < 0.0 1 vs 9 P. M . 
The 24-h pro fi les of melatonin were eva luated by hourly blood 
samples drawn throu gh an ind welling ca thcter, immedi atel y cen-
trifuged at 4°C, and frozen at - 20°C unti l assayed. Plas ma levcls 
were cstimated by radioimmunoassay after diethylether ex trac-
tion using th e method of T iefenauer [9] (Tecova 125 I). The 
reliabi lity o f the melatonin assay was assessed by th e stud y of the 
cross-reactivities with o ther indolamines (S-metho xytryptamine, 
<0.05%; N-acetylserotonin , < 0.02%; Tryptophan, < 0.01 %; se-
roton in, <0.01 %) (no detectable cross- reactivity w ith S-M OP 
used o rall y at the dose of 40 m g) . T he intraassay va riability was 
less than 6% at 0.58 nmollliter concentration. T he sensiti vity o f 
the assay was 0.0228 nmollliter. 
Mean and SEM of hourl y plasma levels of immunoreactive 
melatonin were calculatcd in the different conditions. Considering 
the pretrea tment mea n va lues, respectively 9 A.M . and 9 P.M ., as 
baseline values; the mean incrcase coeffi cients, corrected from the 
baseline variat ions, were ca lculated from 1 h until 4 h after the 
S-M OP administration. The paired I-tes t was used for plas ma 
level comparisons w ithin a g roup and between different condi-
oons, and the Wilcoxon test for comparisons of increase coeffi-
cients and ERG amplitudes. 
RES ULTS 
We present here the acute effect of psoralen on the plasma levels 
of immunoreactive melatonin . Plasma levels are expressed in Ta-
ble I and illustratcd in Fig 1. Morning and evening baseline va lues 
were quite similar in the different conditions. T he plas ma levels 
increased significantl y (p < 0.01) from the third hour after morn-
ing administration and from the second hour after evenin g admin-
is tration ofS-MOP. Compared w ith the standard conditions, this 
rise of plas ma immunoreactive melatonin was highly sign ificant 
after morning (p < 0.01) as well as evening (p < 0.001) trea tm ent. 
Accordin g to the increase coefficient cvaluati ons (corrected from 
basel ine variations) (Table II), the magnitude o f th e immuno-
reactive melatonin response to S-MOP was much higher in the 
da rk phase (after 9 P.M.) than under illumination (at 9 A. M .) (p 
< 0.05). N o side effccts ofS-MOP such as nausea were reported 
by the subj ects in eithcr condition. 
T he sensitivity of the retina light, under photopic conditions 
was significantly enhanced 2 h after S-M OP administration , (p < 
0.05) w ith w hite light and p < 0.01 with o range li ght (Fig 2a). 
Under scotopic conditions, the sensitivity of the retina was sig-
nifi cantly enhan ced after 4 min of dark adaptat ion compared w ith 
that observed after 12 min of dark adaptati on (p < 0.05) (Fig 2b). 
DISCUSSION 
Baseline values of plas ma immunoreactive melatonin were in the 
normal range and quite similar durin g the day period, w hereas 
they were significan tl y increased durin g the dark period, w hich 
is quite consistent with previous reports [6] and w ith the inhib-
iting effect of intense light on melatonin secretion in humans [4]. 
T he response of melatonin to S-MOP administrati on is in linc 
with two previous papers, w hich reported a similar in crease after 
single administration of8-MOP in thc rat [9] and in hum ans [7], 
findings that lead us to consider that the acute more than the 
chronic administration of psora len may be responsible for the 
increased melatonin levels. On the other hand , the lag between 
adm inistration of 5-M OP and th e melatonin res ponse is entirely 
consistent with pharma cokin etics of mcthoxy psoralens in humans 
since peaks of plasm a levels of 5-MOP have been observed 1.5 
h after ora l administration [1 0]. 
The serum melato nin response mi ght first res ult from an in-
hibition of melatonin mctaboli sm. Preliminary studics repo rtin g 
a simil ar increase of 6-hyd roxy melatonin , th e major meta bolite 
of melatonin [3,7], after 8-MOP administration seem to rule out 
this hypothesis. As the rcsponse of melatonin after 8-MOP 
administration has been reported to be higher in no rm al rats than 
in pinealectomized animals [7], the stimulation of the pineal g land 
by pso ralens is likel y to be responsible for the enhancement of 
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Figure 1. Acute responses of plas ma melatonin secretion to 5-MOP. 
Melatonin plasma levels arc illustrated (as hourly mean ± SEM) aftcr both 
morning and evening administrations of 5-MOP and are compared to 
similar profiles observed in baseline conditions (11 = 11 ). 
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Table II. H o url y In crease Coefficients 
+ 1 Hour + 2 Hours + 3 Hours + 4 Hours 
5-MO P (9 h) 
5-MO P (2 1 h) 
Wilcoxon Test 
0.96 ± 0.3 1 
1.59 ± 0.52 
}J < 0.05 
1. 39 :t 0.22 
2.25 :t 0.7 1 
P < 0.05 
1. 58 ± 0.53 
1.87 ± 0.54 
NS 
1.80 ± 0.92 
2.81 ± 0.75 
P < 0.05 
Ho url y in crease coefficients we n: first calculated in ba seline conditio ns. and thcll co rrected in crease coeffi cients were cvalu :ltcd rro m 1- 4 h after 5-M O P mo rn ing or 
evening admin istratiolls (n = 11 ). 
m elatonin levels . This seem s to be consistent w ith th e fact th at 
psoralens m ay act simultaneously at di ffe rent levels: on DNA of 
skin cell s, on pro tein synth esis, on mitochondria, and on enzymes 
111]. This latter acti vity seem s to account for the in creased m el-
anogenesis o bserved under pso ralen ad ministration (even w ith-
out UV A) Ill] and m ay be in volved in the enh anced acti vity o f 
th e pinea l g land after S-MOP administratio n . 
Li ght ma y also be in volved in th e melatonin response to pso-
ralen . We reported that, besides the skin photosensitizin g activity , 
S-MOP was also able to in crease the retinal sensit ivity to li ght 
under indoo r illumination or in darkn ess . The melatonin secretion 
is indeed hig hl y dependent on light intensity , sin ce its secretion 
is inhibited by intense light in anim als [31 and in hum ans [4] . 
These effects of light on the pineal g land ac tivity arc m ediated 
by the retinoh ypothalamic tract . which extends from th e retina 
to th e hypotha lamus. From the suprachiasmatic nucleus, a neural 
path way traverses th e m edial forebrain bundle and the rostral part 
of the tegmentum, terminating in the intero mediol ateral nucleus 
of the upper thoracic segments w here preganglionic sympatheti c 
fibers orig in ate. These neurons synapse w ith postga nglionic neu-
ron s in the superior cervica l gan glia, which partly reenter the 
brain to the pineal g land [1 2]. Our findin g that S-MOP simul-
taneously increased the m elatonin secretion and th e retina sen-
sitivity to light might thus appea r to be controversial; sin ce we 
found that th e retin a sensitivity was enhan ced b y S-MOP under 
photopic conditions, the inhibiting effect o f bri ght light mi ght 
have prevented the mo rning secretio n o f mel atonin observed after 
S-MOP adm inistrati on. 
Light m ay in fact be in volved on ly in the m odulation of the 
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Figure 2. n. Sensitivity of retina to light: b-wave amplitudes . Mcan 
amplitudcs (± SEM) or b-waves of the ERG performed under photopic 
conditions lusing white (opell COIIlIllIlS) and orange (s tipplcd CO IIlIllIl S) Aashes I 
arc iJlusrrated in 11 normal subjects in basel ine conditions and 2 h after 
mornin g administration or 5-MOP. Investigations took place at II A.M. 
S'lInll nsterisk, p < 0.05 vs basel ine; Im-ge nsterisk, p < 0.01 vs baseline. b. 
Adaptation or retina co darkness: b2-wave ampliwdcs. Mcan ampliwdcs 
(+ SEM) of the b2-wave of the ERG performed under scotopic conditions 
(after a 20-min period of dark adaptation) are illustrated after 4 and 12 
min in II normal subjects in basel ine (colli III liS IIwrked diagallnll), ) conditions 
and 2 h after morning adm inistration of 5-MOP (s tippled CO IIllIlIl S). In-
vestigations took placc at 11 A.M. Asrerisk, p < 0.05 vs base line. 
response of the pinea l g land to pso ralen . Corrected in crease coef-
fi cients were indeed found to be different after mornin g and eve-
nin g S-MOP administratio n , indica tin g that darkness alone may 
not be responsibl e for this differential rcsponse of thc mel atonin 
secretion. On the other hand , ERG circadi an rh ythm has been 
repo rted in hum ans- with hi gher sensiti vity of eye to light oc-
currin g in the mornin g [1 3]: the inhibiting effect of light on the 
pinea l res ponse to psora len m ay be more pronoun ced in th e m orn-
in g than in the evenin g, thu s accountin g fo r the different responses 
o f melatonin secretion observed after mornin g and evening 
adm inistration of 5-MOP. Differential anal ys is o f the effect of 
psora len o n ERGs performed under constant ro utine at different 
tim es of th e da y w ill probably hi ghlight this h ypothesis. M ore-
over, this effect of li ght on the response to psoralen m ay also be 
m ediated more directly since the retina has also been reported to 
release mel atonin in vivo ['14]. 
Besides the reported retina-photosensitizing activity of S-MOP. 
we also repo rted a clea r differential effect of 5-M OP on the early 
stages of dark adaptation without an effect on the "slow" phase 
of dark adaptat ion. The scotopi c pro tocol o f the ERG is supposed 
to reAect the visual pigment regeneration that is part of the visual 
cycle in the m ammalian eye [151. Moreover, S-MOP may act on 
different enzym es in skin cells. This .effect ofS-MOP on the early 
sta ge of dark adaptation m ay th erefore be related to an increased 
activity of enzym es in volved in this ea rl y part o f visua l pig m ent 
regeneration , especiall y the l1-cis retino l oxidoreductase, which 
converted the 11-trmrs retinol into 11-ci5 retino l. 
We have thus found th at 5-M OP was able to in crease plasma 
levels of melatonin in hum ans as well as to enh ance retinal sen-
sitivity to light. The form er effect m ay be of great interes t in 
o rder to inves ti ga te the effects of end ogen ous melatonin on di f-
ferent fun ctions in hum ans. The latter effect m ay be of interest 
to clarify the mechanisms of th e pso ral en activity. 
We wisil ra rllnllk Dr . P. Far/ot for ndvice mrd til e COlIpi! COII/pmr)' Iorgmlllill.~ 
rlris srlld), . 
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